Citations

Clear

1432 citation(s) found for "Uk, Nathan".

The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma
Buckarma, EeeLN H. , Werneburg, Nathan W., Conboy, Caitlin B. , Kabashima, Ayano , O’Brien, Daniel R. , Wang, Chen , Smoot, Rory L. , Smoot, Rory L , Wang, Chen , Conboy, Caitlin B , Ilyas, Sumera I.

Mayo Clinic

Molecular Cancer Research | July 9, 2020 | Volume: 18 | Issue: 10 | Pages: 1574-1588

10.1158/1541-7786.mcr-20-0165 | PMID 32646966 Get It

Abstract The Hippo pathway effector Yes-associated protein (YAP) is localized to the nucleus and transcriptionally active in a number of tumor types, including a majority of human cholangiocarcinomas. YAP activity has been linked to chemotherapy resistance and has been shown to rescue KRAS and BRAF inhibition in RAS/RAF-driven cancers; however, the underlying mechanisms of YAP-mediated chemoresistance have yet to be elucidated. Herein, we report that the tyrosine phosphatase SHP2 directly regulates the activity of YAP by dephosphorylating pYAPY357 even in the setting of RAS/RAF mutations, and that diminished SHP2 phosphatase activity is associated with chemoresistance in cholangiocarcinomas. A screen for YAP-interacting tyrosine phosphatases identified SHP2, and characterization of cholangiocarcinomas cell lines demonstrated an inverse relationship between SHP2 levels and pYAPY357. Human sequencing data demonstrated lower SHP2 levels in cholangiocarcinomas tumors as compared with normal liver. Cell lines with low SHP2 expression and higher levels of pYAPY357 were resistant to gemcitabine and cisplatin. In cholangiocarcinomas cells with high levels of SHP2, pharmacologic inhibition or genetic deletion of SHP2 increased YAPY357 phosphorylation and expression of YAP target genes, including the antiapoptotic regulator MCL1, imparting resistance to gemcitabine and cisplatin. In vivo evaluation of chemotherapy sensitivity demonstrated significant resistance in xenografts with genetic deletion of SHP2, which could be overcome by utilizing an MCL1 inhibitor. Implications: These findings demonstrate a role for SHP2 in regulating YAP activity and chemosensitivity, and suggest that decreased phosphatase activity may be a mechanism of chemoresistance in cholangiocarcinoma via a MCL1-mediated mechanism.
The Trio Pulmonary Arterial Hypertension Registry; a Platform Combining EMR Clinical Measures with Pharmacy Prescription and Dispensing Data
Nathan, Steven D. , Chakinala, Murali M. , Frost, Adaani , Farber, Harrison W. , Frantz, Robert P. , Milligan, Scott , Oudiz, Ronald J.

Mayo Clinic

D37. A PULMONARY AND CRITICAL CARE MEDLEY | July 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6593-A6593

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6593 Get It

A Platform to Combine Clinical, Prescription, and Dispensing Data to Better Inform Idiopathic Pulmonary Fibrosis Care; The Trio Registry
Nathan, S.D., Chakinala, Murali M. , Frost, Adaani , Lancaster, Lisa , Milligan, K. R., Frantz, Robert P. , Milligan, K., Milligan, Scott , Oudiz, Ronald J. , Farber, Harrison W.

Mayo Clinic

A37. ILD THERAPY I | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1519-A1519

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1519 Get It

The Six-Minute Walk Test in Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry
Baughman, Robert P. , Nathan, Steven D. , Alhamad, Esam H. , Culver, Daniel A. , Barney, Joseph B. , Porquera, Eva M. Carmona, Huitema, Marloes P. , Scholand, Mary Beth , Ganesh, Sivagini, Birring, SS, Shlobin, Oksana A. , Gupta, Rohit , Wells, A.U., Kouranos, Vasileios , Wijsenbeek, Marlies

Mayo Clinic

A102. ILD DIAGNOSIS AND MONITORING | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2574-A2574

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2574 Get It

A Follow-On Prospective Clinical Validation of the Envisia Genomic Classifier
Scholand, Mary Beth , Nathan, Steven D. , Colby, Thomas V. , Groshong, Steve D. , Lynch, David A. , Lancaster, Lisa , Oldham, Justin, Patel, nbspHemal, Choi, Y. , Pankrantz, D., Bhorade, Sangeeta , Lofaro, Lori , Huang, Jing , Raghu, Ganesh , Chung, Jonathan Hero , Patel, N., Kennedy, G.

Mayo Clinic

A102. ILD DIAGNOSIS AND MONITORING | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2557-A2557

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2557 Get It

Frailty in Patients With Mild Autonomous Cortisol Secretion is Higher Than in Patients with Nonfunctioning Adrenal Tumors
Singh, Sumitabh , Atkinson, Elizabeth J. , Achenbach, Sara J., LeBrasseur, Nathan, LeBrasseur, Nathan K. , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 6, 2020 | Volume: 105 | Issue: 9 | Pages: e3307-e3315

10.1210/clinem/dgaa410 | PMID 32628749 Get It

Abstract Context Mild autonomous cortisol secretion (MACS) affects up to 50% of patients with adrenal adenomas. Frailty is a syndrome characterized by the loss of physiological reserves and an increase in vulnerability, and it serves as a marker of declining health. Objective To compare frailty in patients with MACS versus patients with nonfunctioning adrenal tumors (NFAT). Design Retrospective study, 2003-2018 Setting Referral center Patients Patients >20 years of age with adrenal adenoma and MACS (1 mg overnight dexamethasone suppression (DST) of 1.9-5 µg/dL) and NFAT (DST <1.9 µg/dL). Main outcome measure Frailty index (range 0-1), calculated using a 47-variable deficit model. Results Patients with MACS (n = 168) demonstrated a higher age-, sex-, and body mass index–adjusted prevalence of hypertension (71% vs 60%), cardiac arrhythmias (50% vs 40%), and chronic kidney disease (25% vs 17%), but a lower prevalence of asthma (5% vs 14%) than patients with NFAT (n = 275). Patients with MACS reported more symptoms of weakness (21% vs 11%), falls (7% vs 2%), and sleep difficulty (26% vs 15%) as compared with NFAT. Age-, sex- and BMI-adjusted frailty index was higher in patients with MACS vs patients with NFAT (0.17 vs 0.15; P = 0.009). Using a frailty index cutoff of 0.25, 24% of patients with MACS were frail, versus 18% of patients with NFAT (P = 0.028). Conclusion Patients with MACS exhibit a greater burden of comorbid conditions, adverse symptoms, and frailty than patients with NFAT. Future prospective studies are needed to further characterize frailty, examine its responsiveness to adrenalectomy, and assess its influence on health outcomes in patients with MACS.
The current state of electrocorticography-based brain–computer interfaces
Miller, Kai J. , Staff, Nathan P. , Staff, Nathan P , Hermes, Dora

Mayo Clinic

Neurosurgical Focus | July 1, 2020 | Volume: 49 | Issue: 1 | Pages: E2

10.3171/2020.4.focus20185 | PMID 32610290 Get It

Brain–computer interfaces (BCIs) provide a way for the brain to interface directly with a computer. Many different brain signals can be used to control a device, varying in ease of recording, reliability, stability, temporal and spatial resolution, and noise. Electrocorticography (ECoG) electrodes provide a highly reliable signal from the human brain surface, and these signals have been used to decode movements, vision, and speech. ECoG-based BCIs are being developed to provide increased options for treatment and assistive devices for patients who have functional limitations. Decoding ECoG signals in real time provides direct feedback to the patient and can be used to control a cursor on a computer or an exoskeleton. In this review, the authors describe the current state of ECoG-based BCIs that are approaching clinical viability for restoring lost communication and motor function in patients with amyotrophic lateral sclerosis or tetraplegia. These studies provide a proof of principle and the possibility that ECoG-based BCI technology may also be useful in the future for assisting in the cortical rehabilitation of patients who have suffered a stroke.
The senescence-associated secretome as an indicator of age and medical risk
Schafer, Marissa , Zhang, Xu , Atkinson, Elizabeth J. , Zhu, Yi , Jachim, Sarah K. , Mazula, Daniel L., Brown, Ashley K. , Berning, Michelle J. , Aversa, Zaira, Kotajarvi, Brian R., Greason, Kevin L. , Suri, Rakesh M. , Cummings, Steven R. , White, Thomas A. , Schafer, Marissa J , Zhang, Xu , Zhu, Yi , Kumar, Amanika , Bruce, Charles J. , Tracy, Russell P. , LeBrasseur, Nathan K.

Mayo Clinic

JCI Insight | June 17, 2020 | Volume: 5 | Issue: 12 | Pages: No page available

10.1172/jci.insight.133668 | PMID 32554926 Get It

Produced by senescent cells, the senescence-associated secretory phenotype (SASP) is a potential driver of age-related dysfunction. We tested whether circulating concentrations of SASP proteins reflect age and medical risk in humans. We first screened senescent endothelial cells, fibroblasts, preadipocytes, epithelial cells, and myoblasts to identify candidates for human profiling. We then tested associations between circulating SASP proteins and clinical data from individuals throughout the life span and older adults undergoing surgery for prevalent but distinct age-related diseases. A community-based sample of people aged 20–90 years (retrospective cross-sectional) was studied to test associations between circulating SASP factors and chronological age. A subset of this cohort aged 60–90 years and separate cohorts of older adults undergoing surgery for severe aortic stenosis (prospective longitudinal) or ovarian cancer (prospective case-control) were studied to assess relationships between circulating concentrations of SASP proteins and biological age (determined by the accumulation of age-related health deficits) and/or postsurgical outcomes. We showed that SASP proteins were positively associated with age, frailty, and adverse postsurgery outcomes. A panel of 7 SASP factors composed of growth differentiation factor 15 (GDF15), TNF receptor superfamily member 6 (FAS), osteopontin (OPN), TNF receptor 1 (TNFR1), ACTIVIN A, chemokine (C-C motif) ligand 3 (CCL3), and IL-15 predicted adverse events markedly better than a single SASP protein or age. Our findings suggest that the circulating SASP may serve as a clinically useful candidate biomarker of age-related health and a powerful tool for interventional human studies.
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Kelly, William Kevin, Cheng, Heather H. , Cookson, Michael S. , Dahut, William L. , Weissman, Scott M., Soule, Howard R. , Petrylak, Daniel P. , Dicker, Adam P. , AlDubayan, Saud H. , Pettaway, Curtis A. , Daly, Mary B., Mohler, James L. , Parsons, J. Kellogg , Pilarski, Robert , Blanco, Amie , Woodson, Ashley, Taplin, Mary-Ellen, Polascik, Thomas J. , Hyatt, Colette, Feng, Felix Y. , Mullane, Michael P., Powers, Jacqueline, Concepcion, Raoul S. , Lin, Daniel W. , Wender, Richard C. , Mark, James Ryan , Costello, Anthony J. , Isaacs, William B. , Xu, Jianfeng , Weitzel, Jeffrey N. , Andriole, Gerald L. , Beltran, Himisha , Briganti, Alberto , Byrne, Lindsey , Calvaresi, Anne, Chandrasekar, Thenappan , Chen, David Y.T. , Dobi, Albert , Crawford, E. David , Eastham, James A., Eggener, Scott E. , Freedman, Matthew L. , Garnick, Marc B. , Gomella, Patrick T. , Handley, Nathan , Hurwitz, Mark , Izes, Joseph K. , Karnes, R. Jeffrey , Lallas, Costas D. , Languino, Lucia R. , Loughlin, Kevin R. , Lu‐Yao, Grace , Malkowicz, S. Bruce, Mann, Mark, Mille, Patrick , Miner, Martin , Morgan, Todd M. , Mucci, Lorelei A. , Nielsen, Sarah M. , O’Neil, Brock , Pinover, Wayne H., Pinto, Peter A. , Poage, Wendy, Raj, Ganesh V. , Ryan, Charles J. , Schiewer, Matthew J. , Szymaniak, Brittany M. , Tester, William , Trabulsi, Edouard J. , Vapiwala, Neha , Gomella, Leonard G. , Weitzel, Jeffrey N , Morgan, Todd M , Cheng, Heather H , Dicker, Adam P , Giri, Veda N. , Knudsen, Karen E. , Cooney, Kathleen A. , Toland, Amanda Ewart , Pritchard, Colin C. , Carroll, Peter R , Rahm, Alanna Kulchak , Taplin, Mary‐Ellen , Helfand, Brian T. , Morgans, Alicia K. , Burnett, Arthur L. “Bud” , Sartor, Oliver , Den, Robert B. , Loeb, Stacy , López, Ana María , Moreno, Jose, Myers, Ronald E. , Rebbeck, Timothy R. , Sandler, Howard M. , Scott, E. Michael D., Yu, Evan Y , Zeigler-Johnson, Charnita M

Mayo Clinic

Journal of Clinical Oncology | June 9, 2020 | Volume: 38 | Issue: 24 | Pages: 2798-2811

10.1200/jco.20.00046 | PMID 32516092 Get It

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider). RESULTS Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing—initial testing of priority genes followed by expanded testing—was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches. CONCLUSION This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
Loneliness and Migraine Self-Management: A Cross-Sectional Assessment
Lui, Jacob , Ebbert, Jon O. , Rosedahl, Jordan K., Philpot, Lindsey M. , Lui, Jacob Z, Young, Nathan P. , Philpot, Lindsey M

Mayo Clinic

Journal of Primary Care & Community Health | June 2, 2020 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2150132720924874 | PMID 32484017 Get It

Background: Chronic illness is often comorbid with the psychological state of loneliness. Models of care for patients who experience chronic migraines may often lack an understanding of psychosocial influences of the illness. Addressing the effects of loneliness on the health behaviors of chronic migraine patients may further elucidate gaps in care that exist beyond the biomedical approach to migraine treatment. The primary aim of this study was to assess the relationship between loneliness and behavioral health decisions in chronic migraine patients, specifically patient ability to self-manage, and effectiveness of treatments. Methods: We conducted a cross-sectional survey among patients (n = 500) with migraine and assessed for the experience of loneliness by using the University of California, Los Angeles–Revised (UCLA-R) Three-item Loneliness Scale and the extent of migraine-related disability via the Migraine Disability Assessment (MIDAS). Furthermore, we evaluated patients for their ability to self-manage their migraines, and perceived effectiveness of treatment. Results: Nearly half of our population reported at least one measure of loneliness (230/500, 46.0%). Patients experiencing chronic migraine were statistically more likely to report feeling lonely when compared to patients with episodic migraines ( P < .001). Patients who report loneliness had lower odds of feeling ’very satisfied” with their ability to self-manage their migraine symptoms (aOR = 0.34, 95% CI 0.14-0.81) and had lower odds of feeling “very satisfied” with their ability to avoid conditions that cause their headache (aOR = 0.39, 95% CI 0.16-0.91). Conclusions: Loneliness has significant effects on the illness experience of patients with chronic migraines, including their ability to self-manage or be satisfied with their current state of care. Psychosocial models of care that address loneliness among patients with chronic migraine may help improve health outcomes and management.